John V. Frangioni, M.D., Ph.D., is Founder and CEO of Curadel Pharma, a pharmaceutical company focused on the development and manufacturing of novel imaging and therapeutic agents compliant with both FDA and EMA standards.

He previously served for more than two decades on the faculty of Harvard Medical School as Professor of Medicine and Professor of Radiology, and was an Attending Physician at Beth Israel Deaconess Medical Center. During his academic career, he was Principal Investigator on more than $60 million of NIH, DOE, and other research grants in the field of molecular imaging. He has authored more than 200 peer-reviewed scientific publications, with over 28,000 citations and an H-index of 73.

Dr. Frangioni received his A.B. in Engineering Sciences from Harvard University, his M.D. from Harvard Medical School through the Harvard-MIT Health Sciences and Technology program, and his Ph.D. in Cellular and Molecular Physiology from Harvard University.